• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
  • View Item
  •   LillOA Home
  • Liste des unités
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Enhancement of Adjuvant Functions of Natural ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.3389/fimmu.2017.00879
PMID :
28798749
Title :
Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy
Author(s) :
Ghinnagow, Reem [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Cruz, Luis Javier [Auteur]
Leiden University Medical Center (LUMC)
Macho-Fernandez, Elodie [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Faveeuw, Christelle [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Trottein, Francois [Auteur correspondant]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Journal title :
Frontiers in Immunology
Pages :
879
Publisher :
Frontiers
Publication date :
2017-07-27
ISSN :
1664-3224
English keyword(s) :
CTL response
adjuvant
cancer
dendritic cells
nanovaccines
natural killer T cells
α-galactosylceramide
HAL domain(s) :
Sciences du Vivant [q-bio]/Immunologie/Immunité innée
English abstract : [en]
Type I natural killer T (NKT) cells have gained considerable interest in anticancer immune therapy over the last decade. This "innate-like" T lymphocyte subset has the unique ability to recognize foreign and self-derived ...
Show more >
Type I natural killer T (NKT) cells have gained considerable interest in anticancer immune therapy over the last decade. This "innate-like" T lymphocyte subset has the unique ability to recognize foreign and self-derived glycolipid antigens in association with the CD1d molecule expressed by antigen-presenting cells. An important property of these cells is to bridge innate and acquired immune responses. The adjuvant function of NKT cells might be exploited in the clinics. In this review, we discuss the approaches currently being used to target NKT cells for cancer therapy. In particular, we highlight ongoing strategies utilizing NKT cell-based nanovaccines to optimize immune therapy.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Collections :
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Source :
Harvested from HAL
Files
Thumbnail
  • https://www.hal.inserm.fr/inserm-02436032/document
  • Open access
  • Access the document
Thumbnail
  • https://www.hal.inserm.fr/inserm-02436032/document
  • Open access
  • Access the document
Thumbnail
  • https://www.hal.inserm.fr/inserm-02436032/document
  • Open access
  • Access the document
Université de Lille

Mentions légales
Université de Lille © 2017